open access

Ahead of Print
Research paper
Published online: 2021-04-26
Get Citation

First trimester screening and progesterone levels in HIV positive women under HAART therapy

Ursache Alexandra Iasi12, Tibeica Maria Alexandra12, Onofriescu Mircea12, Luca Alexandru12, Matasariu Daniela Roxana12, Nemescu Dragos12
DOI: 10.5603/GP.a2021.0096
·
Pubmed: 33914306
Affiliations
  1. Women Clinical Hospital, IASI, Romania
  2. Department of Obstetrics and Gynecology, “Grigore T Popa” University of Medicine and Pharmacy, IASI, Romania

open access

Ahead of Print
ORIGINAL PAPERS Obstetrics
Published online: 2021-04-26

Abstract

Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease.  Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.
Material and methods: It was a prospective study that took place between January 2017- December 2019 in ʺCuza-Vodăʺ Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.
Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.
Discussion: These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.
Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.

Abstract

Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease.  Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.
Material and methods: It was a prospective study that took place between January 2017- December 2019 in ʺCuza-Vodăʺ Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.
Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.
Discussion: These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.
Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.

Get Citation

Keywords

HIV; AIDS; pregnancy; antiretroviral therapy

About this article
Title

First trimester screening and progesterone levels in HIV positive women under HAART therapy

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-04-26

DOI

10.5603/GP.a2021.0096

Pubmed

33914306

Keywords

HIV
AIDS
pregnancy
antiretroviral therapy

Authors

Ursache Alexandra Iasi
Tibeica Maria Alexandra
Onofriescu Mircea
Luca Alexandru
Matasariu Daniela Roxana
Nemescu Dragos

References (16)
  1. Dorobăţ CM, Haliciu AM, Bejan C. Interdisciplinary correlations regarding the clinical and paraclinical evaluations in HIV-positive pregnant women. Rev Med Chir Soc Med Nat Iasi. 2014; 118(3): 749–752.
  2. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1(1): a006841.
  3. Smith JH, Whiteside A. The history of AIDS exceptionalism. J Int AIDS Soc. 2010; 13: 47.
  4. Wainberg MA, Jeang KT. 25 years of HIV-1 research — progress and perspectives. BMC Med. 2008; 6: 31.
  5. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007; 37(Suppl 1): S94–S102.
  6. Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014; 28(3): 371–402.
  7. Fanales-Belasio E, Raimondo M, Suligoi B, et al. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita. 2010; 46(1): 5–14.
  8. Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatments: future trends. Infect Disord Drug Targets. 2018; 18(1): 15–22.
  9. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015; 211(1): 10–18.
  10. Price JT, Phiri WM, Freeman BL, et al. Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: a feasibility study. PLoS One. 2020; 15(1): e0224874.
  11. Price JT, Vwalika B, Freeman BL, et al. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. BMC Pregnancy Childbirth. 2019; 19(1): 81.
  12. Papp E, Balogun K, Banko N, et al. Low prolactin and high 20-α-hydroxysteroid dehydrogenase levels contribute to lower progesterone levels in hiv-infected pregnant women exposed to protease inhibitor-based combination antiretroviral therapy. J Infect Dis. 2016; 213(10): 1532–1540.
  13. Musyoki SK, Chelimo K, Mining SK, et al. The trends of progesterone hormone in advancing pregnancy of Human Immunodeficiency Virus-infected women: a cohort study in western Kenya. IJSTR. 2015; 3(7): 6698–6706.
  14. LaVigne KA, Seligman NS, Berghella V. Offering aneuploidy screening to HIV-positive women: routine counselling or not? BJOG. 2011; 118(7): 775–778.
  15. Patil M, Panchanadikar TM, Wagh G. Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India. 2014; 64(2): 116–119.
  16. Chougrani I, Muller F, Marcelin L, et al. Combined first-trimester Down syndrome screening in HIV-infected women. Eur J Obstet Gynecol Reprod Biol. 2016; 203: 274–278.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl